Thermo Fisher Scientific to support BioNTech vaccine production

Thermo Fisher Scientific

Thursday, 28 February, 2019

Thermo Fisher Scientific has signed a multiyear agreement with German immunotherapy company BioNTech, focused on supplying critical raw materials for the manufacturing of precise immunotherapy vaccine candidates.

Under the agreement, Thermo Fisher will supply nucleotides, enzymes and other critical raw materials to support BioNTech’s mRNA manufacturing platform. The four-year, non-exclusive licensing and supply agreement gives BioNTech rights to use Thermo Fisher’s technologies as part of its clinical and commercial manufacturing processes.

“Our portfolio of molecular biology products is now enabling development and commercialisation of multiple individualised therapies and other advanced medicines, and we continue to expand our capabilities to meet increasing demand,” said Gianluca Pettiti, President, Biosciences, Thermo Fisher Scientific. “We share BioNTech’s commitment to deliver life-saving therapies to patients faster, and we look forward to supporting them through clinical trials and post-approval production.”

“The relationship with Thermo Fisher Scientific secures our access to customised material essential for the manufacturing and commercialisation of our RNA-based product candidates,” said Ugur Sahin, MD, co-founder and CEO of BioNTech. “In addition, as a life science services leader, Thermo Fisher can also deliver reagents at the scale needed to expand our manufacturing capacities.”

Please follow us and share on Twitter and Facebook. You can also subscribe for FREE to our weekly newsletters and bimonthly magazine.

Related News

Public trust in scientists rose during the pandemic

During the COVID-19 pandemic, more than three-quarters of people globally said they trust science...

2021 Ramaciotti Awards for biomedical research announced

The Ramaciotti Foundations have awarded over $1.9 million in grants to support biomedical...

New presidents at STA, Aus Academy of Science

Professor Mark Hutchinson has commenced as President of Science & Technology Australia while...


  • All content Copyright © 2021 Westwick-Farrow Pty Ltd